Background
==========

Hepatocellular carcinoma (HCC), a common malignant tumor of the digestive tract, is the third-leading cause of cancer death in the world \[[@b1-medscimonit-23-2736]\] and ranks second in malignant tumor mortality in China \[[@b2-medscimonit-23-2736]\]. Liver cancer has obvious vascular characteristics, the tumor cells of which can produce a variety of vascular growth factor to promote angiogenesis. Based on the above characteristics, anti-tumor angiogenesis strategy research and exploration in HCC patients is particularly necessary and has important clinical significance.

The emergence of targeted drugs presents new hope for the treatment of cancer patients, with higher specificity and relatively minor adverse effects \[[@b3-medscimonit-23-2736]\]. In liver cancer, sorafenib \[[@b4-medscimonit-23-2736]\] and regorafenib \[[@b5-medscimonit-23-2736]\] are clinically proven to be effective oral agents, but the effect is still very limited. At present, there are a large number of molecular-targeted drugs. One such drug is apatinib, which is still in clinical trials and its efficacy is uncertain. In view of this, a currently popular liver cancer research focus is the molecular mechanism underlying the development of HCC and establishing a more effective targeted therapy.

Histone modification plays a key role in tumor progression, including angiogenesis \[[@b6-medscimonit-23-2736]\]. For example, mixed-lineage leukemia 1 (MLL1), as the histone methylase, plays an important role in tumor growth and angiogenesis. Histone deacetylase 3 (HDAC3) can act as a negative regulator of angiogenesis factor. Retinoblastoma-binding protein 2 (RBP2) is a newly discovered histone demethylase that can participate in the development and progression of cancer \[[@b7-medscimonit-23-2736],[@b8-medscimonit-23-2736]\]. Recently, studies have shown that RBP2 also plays an important role in the angiogenesis of cancer \[[@b9-medscimonit-23-2736],[@b10-medscimonit-23-2736]\]. However, the biological and clinical significance of RBP2 in HCC patients remain largely unknown.

Therefore, in the present study, immunohistochemical staining was done to examine the expressions of RBP2, VEGF, and CD31-labeled microvessel density (MVD) in HCC and corresponding adjacent normal tissues. We also investigated RBP2 expression in HCC and its relationships with patient clinicopathological features, prognosis, and angiogenesis.

Material and Methods
====================

Patients and samples
--------------------

The tissue samples were collected from 130 patients diagnosed with HCC after curative operation at Renmin Hospital of Wuhan University from August 2009 to December 2012. Tumor staging was established on the basis of the sixth edition of the tumor-node-metastasis (TNM) classification of the Union for International Cancer Control (UICC). All patients' clinicopathological parameters are summarized in [Table 1](#t1-medscimonit-23-2736){ref-type="table"}. The study was authorized by the Ethics Committee of Renmin Hospital of Wuhan University and abided by the Declaration of Helsinki. Written informed consent was provided by all patients.

Immunohistochemical protocol and analysis
-----------------------------------------

Immunohistochemical staining was done by a two-step method. RBP2, VEGF, and CD31 antibodies were used (the concentration of all antibodies was 1: 100). In brief, the procedure was: (1) Fix tumor tissues with 10% formalin at room temperature; (2) Rinse the tissue with running tap water to eliminate the formaldehyde; (3) Dehydrate the tissues in EtOH baths; (4) Clear the tissue twice in xylene; (5) Melt the paraffin prior to adding the tissue; (6) Pour melted paraffin into a paraffin block mold; (7) Section the paraffin-embedded tissue block in 4-μm-thick slices; (8) Float the tissue sections onto clean glass slides and microwave at 65°C for 15 min, and then store overnight at room temperature; and (9) Establish a negative control by using PBS to replace the primary antibody. Immunohistochemical scores were classified according to a published report \[[@b11-medscimonit-23-2736]\].

MVD counts
----------

MVD counts were labeled by CD31-positive staining vascular endothelial cells. After scanning an immunostained section at low magnification (×40), the regions with maximum number of dramatically marked microvessels stained with anti-CD31 were selected, and microvessels were counted at higher power (×100). All sections were evaluated by 2 pathologists independently.

Statistics and data analysis
----------------------------

Statistical analysis was done using SPSS 19.0 software. The relationship between RBP2 expression and clinicopathological characteristics was examined by Pearson X^2^ test or Fisher test. Kaplan-Meier and Cox regression models were used to determine the survival rates and for multivariate analysis. Statistical significance was defined as *P* \< 0.05.

Results
=======

RBP2 expression and correlation with clinicopathological parameters in HCC
--------------------------------------------------------------------------

Immunohistochemistry was used in 130 cases of HCC and corresponding adjacent normal tissues to detect the clinicopathological and prognostic values of RBP2 in HCC. RBP2 protein staining was mainly located in the cytoplasm ([Figures 1A](#f1-medscimonit-23-2736){ref-type="fig"}, [2A](#f2-medscimonit-23-2736){ref-type="fig"}). RBP2 positive expression rate was 72.3% (94/130) in HCC tissues ([Figure 1](#f1-medscimonit-23-2736){ref-type="fig"}). The correlations of RBP2 expression with clinicopathological factors are summarized in [Table 1](#t1-medscimonit-23-2736){ref-type="table"}. Elevated RBP2 expression was dramatically related to AFP level (P=0.016), degree of differentiation (P=0.000) and TNM stage (P=0.035).

Relationship between RBP2 and VEGF protein expression
-----------------------------------------------------

VEGF staining was mainly located in the cytoplasm ([Figure 2B](#f2-medscimonit-23-2736){ref-type="fig"}); 93 of the 130 HCC tissues were VEGF-positive (71.5%), and the positive rate of both RBP2 and VEGF was 57.7% (75/130). Furthermore, Pearson's test showed a significant relationship between expression of RBP2 and VEGF in tumor tissues (r=0.295, P=0.001; [Table 2](#t2-medscimonit-23-2736){ref-type="table"}).

Correlation between RBP2 and MVD in HCC
---------------------------------------

MVD was counted by examining the CD31 staining to assess the correlation between RBP2 and angiogenesis ([Figure 2C](#f2-medscimonit-23-2736){ref-type="fig"}). RBP2-positive HCC tissues had an evidently higher MVD than in RBP2-negative tissues (P=0.000; [Figure 3](#f3-medscimonit-23-2736){ref-type="fig"}).

Relationship between RBP2 and prognosis
---------------------------------------

Survival analysis showed that RBP2 expression was inversely related to the survival of HCC patients. In comparison to those with negative RBP2 expression, DFS and OS times were significantly decreased in RBP2-positive patients (P=0.000, [Figure 4A](#f4-medscimonit-23-2736){ref-type="fig"} and P=0.000, [Figure 4B](#f4-medscimonit-23-2736){ref-type="fig"}, respectively).

Prognostic values in HCC patients
---------------------------------

Univariate analysis was performed to reveal that RBP2 expression, degree of differentiation, and TNM stage had significant prognostic impacts on DFS and OS ([Tables 3](#t3-medscimonit-23-2736){ref-type="table"}, [4](#t4-medscimonit-23-2736){ref-type="table"}). Furthermore, Cox analysis showed that RBP2 expression was an independent prognostic parameter for DFS (P=0.029) and OS (P=0.010) ([Tables 5](#t5-medscimonit-23-2736){ref-type="table"}, [6](#t6-medscimonit-23-2736){ref-type="table"}).

Discussion
==========

RBP2 belongs to the JARID family and can remarkably demethylate H3K4me2 and H3K4me3 \[[@b12-medscimonit-23-2736]\]. Accumulating evidence demonstrated that RBP2 is abnormally expressed in many kinds of malignant tumors such as gastric cancer \[[@b9-medscimonit-23-2736]\], non-small cell lung cancer (NSCLC) \[[@b10-medscimonit-23-2736]\], and liver cancer \[[@b13-medscimonit-23-2736]\]. These findings show that the function of RBP2 is mainly associated with the epithelial-mesenchymal transition (EMT), migration, invasion, and cell proliferation of cancer. However, whether RBP2 expression is related to HCC angiogenesis and its prognostic value still remain unclear. In the present study, our preliminary findings demonstrated that RBP2 was highly expressed in HCC tissues. Moreover, further results showed that RBP2-positive expression was remarkably related to the AFP level, degree of differentiation, and TNM stage. The above data suggest a pivotal role for RBP2 in progression and development of HCC.

Accumulating research demonstrates that overexpression of VEGF is associated with aggressive behavior and unfavorable prognosis of cancer \[[@b14-medscimonit-23-2736],[@b15-medscimonit-23-2736]\]. Moreover, several studies have demonstrated that increased VEGF expression and MVD are significantly correlated with poorer prognosis in HCC \[[@b16-medscimonit-23-2736],[@b17-medscimonit-23-2736]\]. In our study, a remarkable positive relationship between expression of RBP2 and VEGF was found. In comparison to those with negative RBP2 expression, patients with positive RBP2 expression had a significantly higher MVD, suggesting that RBP2 is involved in HCC tumor angiogenesis, possibly in cooperation with VEGF. Recently, Li et al. \[[@b9-medscimonit-23-2736]\] found that RBP2 can directly bind to the promoter of VEGF to regulate its expression and promote the angiogenesis of gastric cancer by histone H3K4 demethylation. Qi et al. \[[@b10-medscimonit-23-2736]\] found that RBP2 can promote HIF-1α-VEGF-induced angiogenesis of NSCLC via the AKT pathway. The AKT signaling pathway plays an important regulatory role in many cellular survival pathways, primarily in angiogenesis and tumorigenesis, through regulation of VEGF \[[@b18-medscimonit-23-2736]\]. These results suggest that RBP2 may be engaged in promoting VEGF expression through PI3K/AKT/HIF-1α signaling. Furthermore, Fan et al. \[[@b19-medscimonit-23-2736]\] recently reported that miR-34a promotes the osteogenic differentiation of hASCs via the RBP2/NOTCH1/CYCLIN D1 coregulatory network. Therefore, further detailed research is needed to elucidate the role of RBP2 in angiogenesis of HCC.

Next, we explored the clinical significance in prognosis of RBP2 in HCC. Compared to those with RBP2-negative expression, patients with RBP2-positive expression have decreased DFS and OS, as shown by Kaplan-Meir analysis. Univariate and multivariate analyses showed that RBP2 was an independent unfavorable predictor of DFS and OS in HCC patients.

There are several limitations in the present study. Firstly, it was a relatively small-sample, retrospective study, possibly leading to a selective bias. Secondly, we only used immunohistochemical staining, which is a semi-quantitative method, to examine the expression of relative antibodies. Finally, the detailed underlying molecular mechanisms were not explored, which needs to be elucidated in our further studies.

Conclusions
===========

Our preliminary findings demonstrated that increased RBP2 expression is closely related to HCC angiogenesis and is an independent adverse prognostic factor. RBP2 is expected to become a new potential therapeutic target for HCC.
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![Immunochemical staining of RBP2 in HCC tissues. (**A**) High positive expression of RBP2; (**B**) Low positive expression of RBP2; (**C**) Negative expression of RBP2. (with 100× magnification).](medscimonit-23-2736-g001){#f1-medscimonit-23-2736}

![(**A--C**) Positive co-expression of RBP2, VEGF, and CD31 in HCC tissues, confirmed by immunochemical staining (400× magnification).](medscimonit-23-2736-g002){#f2-medscimonit-23-2736}

![Intratumoral microvessel density (MVD) in relation to RBP2 protein immunoreactivity. HCC patients with RBP2-positive expression showed significantly higher intratumoral MVD than in patients with RBP2-negative expression (*P*=0.000).](medscimonit-23-2736-g003){#f3-medscimonit-23-2736}

![Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) curves of HCC patients based on RBP2 expression as positive or negative. (**A**) DFS curve of HCC patients based on RBP2 expression; (**B**) OS curve of HCC patients based on RBP2 expression.](medscimonit-23-2736-g004){#f4-medscimonit-23-2736}

###### 

Relationships between RBP2 protein expression in HCC tissues and clinicopathological variables.

  Variables                   Total   RBP2 expression                 
  --------------------------- ------- ----------------- ---- -------- -------
  Gender                                                              
   Male                       106     33                73   3.393    0.065
   Female                     24      3                 21            
  Age at surgery (yeas)                                               
   ≤60                        90      24                66   0.154    0.695
   \>60                       40      12                28            
  Tumor size (cm)                                                     
   ≤5                         62      21                41   2.260    0.133
   \>5                        68      15                53            
  HbsAg                                                               
   Negative                   19      5                 14   0.021    0.885
   Positive                   111     31                80            
  Cirrhosis                                                           
   No                         10      2                 8    0.320    0.572
   Yes                        120     34                86            
  Child-Pugh                                                          
   A                          124     36                88   2.409    0.121
   B                          6       0                 6             
  AFP (ng/ml)                                                         
   ≤20                        44      18                26   5.802    0.016
   \>20                       86      18                68            
  Degree of differentiation                                           
   Well/moderate              71      35                36   36.463   0.000
   Poor and not               59      1                 58            
  TNM stage                                                           
   I/II                       99      32                67   4.446    0.035
   III/IV                     31      4                 27            

###### 

Expression correlation of RBP2 and VEGF in HCC tissues.

  Group             RBP2 expression   *r*   *P*-value   
  ----------------- ----------------- ----- ----------- -------
  VEGF expression                           0.295       0.001
   Positive         75                18                
   Negative         19                18                

###### 

Univariate analysis of the correlation between clinicopathological parameters and disease free survival time of HCC patients.

  Variable                    Mean survival time (m)   95% CI           P
  --------------------------- ------------------------ ---------------- ---------
  Gender                                                                
   Male                       32.256                   20.793--43.719   0.843
   Female                     28.854                   24.038--33.669   
  Age at surgery (yeas)                                                 
   ≤60                        30.910                   25.438--36.382   0\. 319
   \>60                       22.316                   17.729--26.902   
  Tumor size (cm)                                                       
   ≤5                         33.435                   26.636--40.234   0.120
   \>5                        24.766                   19.587--29.945   
  HbsAg                                                                 
   Negative                   29.906                   25.081--34.731   0\. 307
   Positive                   20.632                   15.972--25.291   
  Cirrhosis                                                             
   No                         29.291                   24.689--33.893   0.755
   Yes                        23.600                   18.195--29.005   
  Child-Pugh                                                            
   A                          29.791                   25.287--34.294   0.034
   B                          12.667                   4.671--20.662    
  AFP (ng/ml)                                                           
   ≤20                        32.007                   30.650--43.410   0.127
   \>20                       28.649                   23.388--33.910   
  Degree of differentiation                                             
   Well/moderate              32.825                   27.433--38.217   0.013
   Poor and not               18.965                   13.862--24.069   
  TNM stage                                                             
   I/II                       39.352                   32.666--46.038   0.000
   III/IV                     16.549                   13.397--19.701   
  RBP2 expression                                                       
   Negative                   47.323                   38.148--56.228   0.000
   Positive                   22.140                   17.965--26.315   

###### 

Univariate analysis of the correlation between clinicopathological parameters and overall survival time of HCC patients.

  Variable                    Mean survival time (m)   95% CI           P
  --------------------------- ------------------------ ---------------- ---------
  Gender                                                                
   Male                       32.341                   21.511--43.171   0.943
   Female                     30.505                   26.228--34.781   
  Age at surgery (yeas)                                                 
   ≤60                        31.999                   26.799--37.199   0\. 389
   \>60                       27.550                   22.750--32.350   
  Tumor size (cm)                                                       
   ≤5                         34.738                   28.539--40.938   0.082
   \>5                        27.087                   22.083--32.092   
  HbsAg                                                                 
   Negative                   31.652                   27.185--36.119   0\. 361
   Positive                   23.592                   17.896--29.288   
  Cirrhosis                                                             
   No                         30.650                   26.405--34.894   0.665
   Yes                        28.700                   21.558--35.842   
  Child-Pugh                                                            
   A                          31.220                   27.112--35.328   0.104
   B                          15.667                   5.529--25.804    
  AFP (ng/ml)                                                           
   ≤20                        37.030                   30.650--43.410   0.016
   \>20                       28.649                   23.388--33.910   
  Degree of differentiation                                             
   Well/moderate              33.340                   28.324--38.356   0.034
   Poor and not               23.492                   17.595--29.389   
  TNM stage                                                             
   I/II                       40.293                   34.167--46.420   0.000
   III/IV                     19.677                   16.115--23.239   
  RBP2 expression                                                       
   Negative                   48.395                   40.477--56.344   0.000
   Positive                   23.670                   20.000--27.341   

###### 

Multivariate analysis of the correlation between clinicopathological parameters and disease free survival time of HCC patients.

  Covariates                                           HR      95% CI for HR   *P*
  ---------------------------------------------------- ------- --------------- -------
  Gender (Male *vs.* Female)                           0.739   0.413--1.324    0.310
  Age (≤60 *vs.* \>60 cm)                              0.622   0.385--1.005    0.052
  Tumor size (≤5 *vs.* \>5 cm)                         0.610   0.378--1.985    0.043
  HbsAg (negative *vs.* positive)                      1.654   0.813--3.362    0.165
  Cirrhosis (No *vs.* Yes)                             1.127   0.410--3.097    0.817
  Child-Pugh (A *vs.* B)                               0.547   0.185--1.618    0.276
  AFP (≤20 *vs.* \>20 ng/ml)                           0.906   0.547--1.500    0.700
  Differentiation (Well/moderate *vs.* Poor and not)   0.835   0.494--1.411    0.501
  TNM stage (stage I/II *vs.* III/IV)                  0.309   0.168--0.569    0.000
  RBP2 expression (negative *vs.* positive)            0.476   0.244--0.925    0.029

###### 

Multivariate analysis of the correlation between clinicopathological parameters and overall survival time of HCC patients.

  Covariates                                           HR      95% CI for HR   *P*
  ---------------------------------------------------- ------- --------------- -------
  Gender (Male *vs.* Female)                           0.828   0.460--1.491    0.529
  Age (≤60 *vs.* \>60 cm)                              0.722   0.718--1.624    0.177
  Tumor size (≤5 *vs*. \>5 cm)                         0.592   0.365--0.960    0.034
  HbsAg (negative *vs.* positive)                      1.998   1.000--3.989    0.050
  Cirrhosis (No *vs.* Yes)                             0.531   0.192--1.466    0.222
  Child-Pugh (A *vs.* B)                               0.745   0.253--2.192    0.593
  AFP (≤20 *vs.* \>20 ng/ml)                           0.707   0.425--1.176    0.182
  Differentiation (Well/moderate *vs.* Poor and not)   0.945   0.554--1.611    0.835
  TNM stage (stage I/II *vs.* III/IV)                  0.377   0.208--0.681    0.001
  RBP2 expression (negative *vs.* positive)            0.414   0.211--0.812    0.010
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